Although ulcerative colitis (UC) is confined to colonic and rectal mucosa in a continuous fashion, recent studies have also demonstrated the involvement of upper gastrointestinal tract as diagnostic endoscopy becomes more available and technically advanced. The pathogenesis of UC is not well established yet. It might be associated with an inappropriate response of host mucosal immune system to gut microflora. Although continuous and symmetric distribution of mucosal inflammation from rectum to colon is a typical pattern of UC, clinical feature and course of atypically distributed lesions in UC might also help us understand the pathogenesis of UC. Herein, we report a case of duodenal involvement of UC which successfully remitted after infliximab therapy. Endoscopic and pathologic findings before and after administration of anti-tumor necrosis factor suggest that the pathogenesis of upper gastrointestinal involvement of UC may be similar to that of colon involvement.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505096PMC
http://dx.doi.org/10.5217/ir.2018.00122DOI Listing

Publication Analysis

Top Keywords

ulcerative colitis
8
infliximab therapy
8
upper gastrointestinal
8
remission diffuse
4
diffuse ulcerative
4
ulcerative duodenitis
4
duodenitis patient
4
patient ulcerative
4
colitis infliximab
4
therapy case
4

Similar Publications

Background: Inflammatory bowel disease (IBD) is a chronic disease that includes Crohn's disease and ulcerative colitis. Studies found that 40-60% of women diagnosed with IBD have sexual dysfunction (SD).

Aims: To determine SD and associated factors in women with IBD.

View Article and Find Full Text PDF

Cyclosporine A is an immunosuppressive drug used in clinics to treat steroid-refractory ulcerative colitis (UC). However, due to its side effects, researchers are evaluating novel drug delivery-based treatment options. Nanoparticles-based cyclosporine (Nano-CSA) offers a promising option for the treatment of UC, and various in vivo studies on animals have been conducted.

View Article and Find Full Text PDF

C9orf72 Alleviates DSS‑Induced Ulcerative Colitis via the cGAS-STING Pathway.

Immun Inflamm Dis

January 2025

Department of Health Care, Qingdao Municipal Hospital, Qingdao, Shandong, China.

Purpose: C9orf72 deficiency contributes to severe inflammation in mice. Ulcerative colitis (UC) is a chronic inflammatory disorder with the shortage of clinical success. However, whether C9orf72 is involved in the progression of UC is not fully understood.

View Article and Find Full Text PDF

We present an interesting case of severe ulcerative colitis flare, of challenging management because of a cytomegalovirus co-infection, in which upadacitinib achieved clinical and biochemical remission after poor responses to ganciclovir and tofacitinib.

View Article and Find Full Text PDF

Telocytes in inflammatory bowel diseases: contributions to pathology and therapeutic potentials.

Front Cell Dev Biol

January 2025

Division of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Hershey, PA, United States.

Telocytes, a novel mesenchymal cell population, are characterized by their distinctive long and slender projections known as telopodes and have garnered significant interest since their formal introduction to the literature in 2010. These cells have been identified in various tissues, including the gastrointestinal (GI) tract, where they are suggested to play important roles in maintaining structural integrity, immune modulation, and barrier function. Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), are characterized by chronic inflammation and fibrosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!